Skip to main content
. 2022 Jul 15;15:94. doi: 10.1186/s13045-022-01311-6

Table 3.

Combination therapy with the bypass pathway target

Target Representative compound* Structure Reference
MET Cabozantinib graphic file with name 13045_2022_1311_Figx_HTML.gif [145, 146]
MET Crizotinib graphic file with name 13045_2022_1311_Figy_HTML.gif [147]
MET Savolitinib graphic file with name 13045_2022_1311_Figz_HTML.gif [148]
FGFR AZD4547 graphic file with name 13045_2022_1311_Figaa_HTML.gif [149]
ALK Lorlatinib graphic file with name 13045_2022_1311_Figab_HTML.gif [150]
ALK Brigatinib graphic file with name 13045_2022_1311_Figac_HTML.gif [151]
HER2 JQ1 graphic file with name 13045_2022_1311_Figad_HTML.gif [152]
HER2 Trastuzumab-DM1 graphic file with name 13045_2022_1311_Figae_HTML.gif [153]
BRAF V600E Encorafenib (LGX818) graphic file with name 13045_2022_1311_Figaf_HTML.gif [64]
AURK B PF-03814735 graphic file with name 13045_2022_1311_Figag_HTML.gif [60, 154]

*Osimertinib is a representative third-generation EGFR-TKI